Feasibility and role for comprehensive molecular evaluation for Advanced Biliary Cancer (ABC) in Australia.

Australasian Gastro-Intestinal Cancer Trials Group (AGITG)0 个研究点目标入组 50 人开始时间: 2022年7月28日最近更新: 2023年3月13日

试验速览

暂无简介。

•1.Males or females with suspected advanced biliary tract cancer as determined by MDT review that is either:
•a.Locally advanced
•b.Metastatic
•c.Recurrent
•2.Study participants either:
•a.Are scheduled for an endoscopic procedure for the purposes of tissue diagnosis or biliary stenting
•b.Have previously consented to biobanking of endoscopic biopsy material
•3.Study participants must be 18 years of age or older at time of screening
•4.ECOG Performance Status 0-2
•5.Suitability for chemotherapy
•6.Able to give signed informed consent
•7.Life expectancy of at least 3 months from the time of screening as judged by screening investigator

•1.Patients considered to have operable or potentially operable biliary cancer (BC)
•2.Patients with hepatocellular cancer or liver metastatic disease in which the primary malignancy is not BC.
•3.Evidence of systemic disease (cardiovascular, respiratory, renal, hepatic, etc.) that would preclude chemotherapy.
•4.Serious medical or psychiatric conditions that might compromise protocol-based management as judged by investigator

发起方

Australasian Gastro-Intestinal Cancer Trials Group (AGITG)